MorphoSys (ETR:MOR – Get Rating) received a €11.00 ($11.70) price target from JPMorgan Chase & Co. in a report issued on Monday, Borsen Zeitung reports. JPMorgan Chase & Co.‘s price objective suggests a potential downside of 21.26% from the stock’s current price.
MOR has been the topic of a number of other reports. The Goldman Sachs Group set a €12.00 ($12.77) price objective on shares of MorphoSys in a research note on Tuesday, January 3rd. Morgan Stanley set a €12.50 ($13.30) target price on shares of MorphoSys in a report on Friday. Finally, Deutsche Bank Aktiengesellschaft set a €13.00 ($13.83) target price on shares of MorphoSys in a report on Friday, November 25th.
MorphoSys Price Performance
Shares of MOR stock opened at €13.97 ($14.86) on Monday. MorphoSys has a 52-week low of €13.90 ($14.79) and a 52-week high of €36.02 ($38.32). The stock has a market cap of $477.22 million and a PE ratio of -0.79. The company has a debt-to-equity ratio of 231.51, a quick ratio of 3.49 and a current ratio of 3.76. The firm’s 50 day moving average price is €15.61 and its two-hundred day moving average price is €18.73.
MorphoSys Company Profile
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
- Will LI Auto Be the Least Hated Chinese EV Stock in 2023?
- Which Streaming Service Stock is Best in 2023?
- Here’s Why Snap Stock Can Double in 2023
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.